PCM
CBAY

Prelude Capital Management’s Cymabay Therapeutics CBAY Stock Holding History

Prelude Capital Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,500
Closed -$5K – 2483
2020
Q2 		$5K Buy
+1,500
New +$4.33K ﹤0.01% 1727
2019
Q1 		– Sell
-100
Closed -$1K – 2287
2018
Q4 		$1K Buy
+100
New +$952 ﹤0.01% 1724

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Prelude Capital Management's CBAY Position: Q2 2023 in Review

Prelude Capital Management sold out of Cymabay Therapeutics (CBAY) in Q2 2023, closing a stake of 10,973 shares — an estimated $95.7K sold.

Prelude Capital Management first reported a position in CBAY in Q3 2017 and held it in 7 quarters. The position peaked at $95.7K in Q1 2023. 151 funds tracked by Wall St. Rank hold CBAY as of Q2 2023.

  • Prelude Capital Management reported no remaining Cymabay Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Prelude Capital Management sold 10,973 Cymabay Therapeutics shares in Q2 2023, an estimated $95.7K.
  • Prelude Capital Management first reported a position in Cymabay Therapeutics in Q3 2017 and held it in 7 quarters.
  • Prelude Capital Management's Cymabay Therapeutics position peaked at $95.7K in Q1 2023.
  • 151 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2023.

Based on Prelude Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.